DADidem Alboğa

Didem Alboğa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Didem Alboğa has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and Genetic Landscape of Primary Ciliary Dyskinesia in Turkey: A Single‐Center Retrospective Cohort Study on Genotype–Phenotype Correlations

    by Aslı Kuzu Kuşaklı, Nagehan Emiralioğlu, Birce Sunman, Meltem Akgül Erdal, Didem Alboğa, Burcu Çapraz Yavuz, Sevilay Karahan, Elif Karakoç, Elmas Ebru Yalçın, Deniz Doğru Ersöz, et al.

    Background: Primary ciliary dyskinesia (PCD) is a genetic disorder impairing mucociliary clearance. This study provides a comprehensive analysis of clinical and genetic characteristics in a large Turkish cohort with frequent parental consanguinity. Methods: A retrospective cohort study was performed on 145 patients (selected from 361) with regular follow‐up since 2017 to ensure longitudinal data consistency. The diagnostic work‐up included nasal nitric oxide measurement and high‐speed videomicroscopy, while confirmation was established through genetic testing and/or transmission electron microscopy. Patients were classified according to the 2025 ATS/ERS diagnostic framework. Patients were evaluated for clinical predictors, longitudinal pulmonary function, and genotype–phenotype correlations based on structural protein localization. Results: Among 145 patients (mean age 15.91 ± 6.26 years), early diagnosis was significantly associated with neonatal respiratory distress syndrome ( p = 0.014), NICU admission ( p < 0.001), situs inversus totalis ( p < 0.001), and congenital heart disease ( p < 0.001). The mean PICADAR score was 7.8 ± 3.4, showing a moderate negative correlation with age at diagnosis ( r = −0.50, p < 0.001). According to the 2025 ATS/ERS diagnostic framework, 63 patients (43.4%) were classified as confirmed PCD, 13 (9.0%) as PCD highly likely, and 69 (47.6%) as suspected PCD. Among confirmed PCD patients, the most frequent genetic findings were DNAH5, CCDC40 , and DNAAF1 . Lower final FEV1 values were observed in selected rare genotype subgroups, particularly CCNO , although variant‐specific comparisons were limited by small subgroup sizes. Conclusion: Early recognition of neonatal respiratory distress requiring NICU admission and laterality defects, particularly situs inversus totalis, remains critical for reducing diagnostic delay. In populations with high consanguinity, genetic testing is particularly important for confirming diagnosis and identifying potentially high‐risk genotypes. Multidisciplinary follow‐up focusing on nutrition, infection control, and preservation of lung function is essential for long‐term care in PCD.

  • Open Access

    Foreign body aspiration through the eyes of a pediatric pulmonologist: Is it possible to reduce the rate of negative rigid bronchoscopies?

    by Birce Sunman, Halime Nayır Büyükşahin, İsMail Güzelkaş, Didem Alboğa, Meltem Akgül Erdal, Havva İpEk Demir, Raziye Atan, Burcu Çapraz Yavuz, Burak Ardıçlı, İdIl Rana User, et al.

    Background. Identifying a foreign body aspiration (FBA) still remains a diagnostic difficulty. Moreover, the indications for bronchoscopy in subjects of suspected foreign bodies are not clear. The aim of this study was to evaluate the effectiveness of pediatric pulmonologists in diagnosing FBA. Methods. This was a retrospective, single-center study on children who underwent rigid bronchoscopy for suspected FBA. Data on the patients were obtained from the medical records. Patients who had foreign bodies (FB) identified during rigid bronchoscopy were classified as FB positive, and those in whom rigid bronchoscopy did not detect FB were defined as FB negative. Demographic data as well as consultation status with a pediatric pulmonologist were compared between these two groups. Furthermore, the patients were categorized into three groups based on their clinical scores that assessed the likelihood of the presence of FB: low risk, moderate risk, and high risk. Results. Out of 474 rigid bronchoscopies, 232 (48.9%) detected FB. Consultation by a pediatric pulmonologist was not requested in 388 (81.8%). Out of these 388 patients, 206 (53%) were negative for FB. In terms of FB detection success, there was no difference between individuals who sought pulmonology consultation and those who did not (58.1% vs. 53.1% respectively, p=0.059). However, when the children were categorized based on their risk levels, the incidence of detecting FB among children in low-risk group was 42% when they received consultation from the pulmonology department, whereas this incidence dropped to 5.6% when pulmonology consultation was not sought (p<0.001). Conclusions. Consulting a pediatric pulmonologist, particularly for low-risk individuals, might reduce the likelihood of performing unnecessary bronchoscopies. Given that rigid bronchoscopy is an intrusive technique, it is crucial to reduce the number of negative bronchoscopies in order to mitigate complications associated with it.


  • Open Access

    The Coronavirus Disease 2019 Pandemic and Time to Diagnosis for Childhood Pulmonary Diseases: Outcomes of a Tertiary Care Center

    by Meltem Akgül Erdal, Halime Nayır Büyükşahin, İsMail Güzelkaş, Birce Sunman, Didem Alboğa, Nagehan Emiralioğlu, Ebru Yalçın, Deniz Doğru, H. Uğur Özçelik, Nural Kiper

    Objectives: Coronavirus disease 2019 pandemic caused many changes in the social behaviors of individuals and the provision of health systems. Many studies revealed reductions in the number of diagnoses and delays in diagnosis time during the pandemic. This study aimed to evaluate the effect of the pandemic on the time to diagnosis of major diseases of pediatric pulmonology. Materials and Methods: Newly diagnosed patients with cystic fibrosis (CF), childhood interstitial lung disease (chILD), tuberculosis (TB), and primary ciliary dyskinesia (PCD) were grouped into pandemic (group 1) and 2 consecutive pre-pandemic periods divided into equal intervals (groups 2 and 3). For each disease group, the time to diagnosis was compared between the specified periods. Results: A total number of patients were 171 in this study. In the CF group, there was no statistically difference in time to diagnosis between periods. In the chILD group, there was a statistically significant difference in time to diagnosis (P = .036) between groups (group 1: 2 months, group 2: 4 months and group 3: 10.5 months) that was not originated from pandemic period. In TB group there was no statistically significant difference between groups. In the PCD group, the impact of the pandemic on the time to diagnosis could not be clarified because the time interval to diagnosis (minimum: 2 years, maximum: 16 years) exceeded the studied periods (21 months). Conclusion: In our study, no effect found between the pandemic and age at diagnosis or time to diagnosis in patients with PCD, chILD, CF, and TB at our center. Cite this article as: Akgül Erdal M, Nayır Büyükşahin H, Güzelkaş İ, et al. The coronavirus disease 2019 pandemic and time to diagnosis for childhood pulmonary diseases: Outcomes of a tertiary care center. Turk Arch Pediatr. 2024;59(4):370-374.


  • Open Access

    Nintedanib Treatment in a Child with Pulmonary Fibrosis

    by Meltem Akgül Erdal, Didem Alboğa, Birce Sunman, Hatice Nursun Özcan, Nagehan Emi̇rali̇oğlu, Ebru Yalçın, Deniz Doğru, Uğur Özçeli̇k, Nural Ki̇per

    Çocuklarda pulmoner fibrozis (PF) çok nadir görülen, ilerleyici ve yaşamı tehdit eden bir durumdur. Nintedanib gibi antifibrotiklerin onaylanmasıyla erişkinlerde idiyopatik PF tedavisinde ilerlemeler kaydedilmiştir. Bununla birlikte, çocuklarda PF tedavisi hala daha fazla çalışılması gereken sonuçsuz bir alandır. Burada, PF'li bir çocukta nintedanib deneyimini sunuyoruz.


  • Evaluation of polysomnography findings in children with genetic skeletal disorders

    by Halime Nayır Büyükşahin, Nagehan Emiralioglu, Pelin Özlem Simşek Kiper, Birce Sunman, Ismail Güzelkaş, Didem Alboğa, Meltem Akgül Erdal, Koray Boduroglu, Gülen Eda Utine, Ebru Yalcın, et al.

    Summary: Children with genetic skeletal disorders have variable conditions that can lead to sleep‐disordered breathing, and polysomnography is the gold standard for diagnosing this condition. We aimed to review polysomnography findings, to assess the severity of sleep apnea, and to investigate the clinical variables predictive of sleep‐disordered breathing in these patients. We retrospectively collected the medical records of patients with genetic skeletal disorders who underwent polysomnography for 5 years. Twenty‐seven children with various genetic skeletal disorders, including achondroplasia (14), Crouzon syndrome (3), acromesomelic dysplasia Maroteaux type (3), Apert syndrome (2), osteopetrosis (1), Jeune dysplasia (1), Desbuquois dysplasia (1), acrodysostosis (1), and spondyloepiphyseal dysplasia (1) were enrolled. The median age at the first polysomnography was 58 (1st–3rd quartile: 31–113) months. The overall sleep‐disordered breathing results were: 19 (70.3%) had obstructive sleep apneas (OSA) (4 mild, 6 moderate, 9 severe), 2 (7.4%) had central apneas, 4 (14.8%) had nocturnal hypoventilation. There was a significant correlation between non‐ambulatory status with both total AHI and OSA (p < 0.001, rho: −0.66/p = 0.04, rho: 0.38, respectively). Nine patients received positive airway pressure titration, and the oAHI values of all returned to the normal range. These patients were started with positive airway pressure treatment. Our cohort showed that the majority of the patients with skeletal dysplasia had sleep apnea syndrome characterised mainly by OSA, highlighting the importance of polysomnography screening for sleep disorders. Positive airway pressure therapy represents an effective treatment for sleep‐disordered breathing in those patients.